tiprankstipranks
Trending News
More News >

Cocrystal Pharma Holds 2025 Annual Stockholders Meeting

Story Highlights
Cocrystal Pharma Holds 2025 Annual Stockholders Meeting

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Cocrystal Pharma ( (COCP) ).

On June 25, 2025, Cocrystal Pharma, Inc. held its 2025 Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and strategic plans. Stockholders elected six board members for a one-year term, ratified Weinberg & Company as the independent accounting firm for 2025, and approved the 2025 Equity Incentive Plan. Due to sufficient votes, the proposal to adjourn the meeting was deemed unnecessary.

The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.

Spark’s Take on COCP Stock

According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.

Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.

To see Spark’s full report on COCP stock, click here.

More about Cocrystal Pharma

Average Trading Volume: 20,090

Technical Sentiment Signal: Sell

Current Market Cap: $15.16M

For detailed information about COCP stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1